ICAM1 and Miyoshi myopathy: To maximize the sensitivity and utility of these CRISPR screens, Cas9-engineered MM lines were first selected for exceptional exonuclease activity as determined by reduction in CD54 levels following expression of a CD54-targeted single guide RNA (sgRNA) (Fig. 1a).